Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock investors bought 1,002 put options on the stock. This is an increase of 1,791% compared to the average daily volume of 53 put options.

Insider Activity at Maravai LifeSciences

In other news, insider Carl Hull acquired 175,000 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was bought at an average price of $5.64 per share, with a total value of $987,000.00. Following the transaction, the insider now directly owns 175,000 shares in the company, valued at approximately $987,000. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.63% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC grew its holdings in shares of Maravai LifeSciences by 310.2% during the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company's stock worth $26,000 after purchasing an additional 2,711 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Maravai LifeSciences during the 2nd quarter worth approximately $32,000. Headlands Technologies LLC acquired a new stake in Maravai LifeSciences during the 1st quarter worth approximately $42,000. Blue Trust Inc. bought a new stake in Maravai LifeSciences during the 2nd quarter worth approximately $44,000. Finally, Venturi Wealth Management LLC acquired a new position in Maravai LifeSciences in the 3rd quarter valued at approximately $47,000. Institutional investors own 50.25% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on MRVI. Morgan Stanley lowered shares of Maravai LifeSciences from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $11.00 to $10.00 in a research report on Tuesday, August 13th. William Blair restated a "market perform" rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Robert W. Baird decreased their target price on Maravai LifeSciences from $10.00 to $9.00 and set an "outperform" rating on the stock in a research report on Friday, November 8th. UBS Group lifted their price target on Maravai LifeSciences from $8.50 to $11.00 and gave the stock a "neutral" rating in a report on Thursday, August 8th. Finally, Wells Fargo & Company started coverage on Maravai LifeSciences in a report on Tuesday, August 27th. They issued an "overweight" rating and a $10.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.33.

Maravai LifeSciences Price Performance

Shares of NASDAQ:MRVI traded down $0.30 during midday trading on Thursday, hitting $5.33. The stock had a trading volume of 922,977 shares, compared to its average volume of 2,258,751. The company's 50-day moving average price is $7.92 and its 200-day moving average price is $8.46. Maravai LifeSciences has a fifty-two week low of $4.68 and a fifty-two week high of $11.56. The company has a quick ratio of 9.28, a current ratio of 10.00 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $1.34 billion, a P/E ratio of -3.18 and a beta of 0.02.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.